| Literature DB >> 32645288 |
Monica M Matsumoto1, Scott Widemon2, Geerlitte Farfán3, Tatiana Vidaurre4, Jorge Dunstan5, Debra E Krotish6, Daron G Ferris7, José M García Santos8, Daniel J Mollura9, Erica Pollack10, John R Scheel11.
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32645288 PMCID: PMC7338027 DOI: 10.1016/j.jacr.2020.06.003
Source DB: PubMed Journal: J Am Coll Radiol ISSN: 1546-1440 Impact factor: 5.532
Fig 1Stakeholder relationships and responsibilities in the early breast cancer detection program, utilizing clinical breast examination (CBE) and ultrasound (US), in Cusco, Peru. Patients with a positive CBE will undergo a breast US on site. Patients with a BI-RADS 1/2 or 3 finding on US will be managed clinically or with imaging. Patients with a BI-RADS 4 or 5 US finding will undergo a biopsy or fine needle aspiration with tissue analysis performed at the Centro Oncológico Regional (COR) in Cusco until CerviCusco develops the capacity. A patient with positive tissue diagnosis will be managed either at COR or the Instituto Nacional de Enfermedades Neoplásicas (INEN) in Lima, depending on disease severity and treatment needs. Club de la Mama will provide support for survivors.
Characteristics of women undergoing asymptomatic (screening) and symptomatic (diagnostic) examinations
| Reason for consult, N (%) | |||
|---|---|---|---|
| Characteristic | Screening (n = 148) | Diagnostic (n = 72) | Total (n = 220) |
| Age, median (IQR) | 42 (32-52) | 35.5 (28.5-44) | 40 (31-50) |
| Age at first pregnancy, median (IQR) | 22 (19-26) | 23 (20-26) | 22.5 (19.5-26) |
| Gravida (mean ± SD) | 2.7 ± 1.7 | 2.5 ± 2.2 | 2.6 ± 2.0 |
| Contraceptive use, n (%) | 34 (23.0) | 25 (34.7) | 59 (26.8) |
| Hormone therapy, n (%) | 4 (2.7) | 2 (2.8) | 6 (2.7) |
| Breastfeeding, n (%) | 60 (40.5) | 34 (47.2) | 94 (42.7) |
| Family history, n (%) | |||
| Breast cancer | 22 (14.9) | 9 (12.5) | 31 (14.1) |
| Ovarian cancer | 6 (4.0) | 5 (6.9) | 11 (5.0) |
| Alcohol use, n (%) | 24 (16.2) | 13 (18.1) | 37 (16.8) |
| Prior breast examination(s), n (%) | |||
| None | 113 (76.3) | 36 (50.0) | 149 (67.7) |
| Ultrasound | 15 (10.1) | 25 (34.7) | 40 (18.2) |
| Mammogram | 26 (17.6) | 12 (16.7) | 38 (17.3) |
| Biopsy | 3 (2.0) | 3 (4.2) | 6 (2.7) |
IQR = interquartile range.
Total percentages may be >100% because patients may have received >1 prior examination.
Findings and management of women undergoing asymptomatic (screening) and symptomatic (diagnostic) examinations
| Reason for consult, N (%) | |||
|---|---|---|---|
| Category | Screening (n = 148) | Diagnostic (n = 72) | Total (n = 220) |
| Breast-related complaint(s), n (%) | |||
| None | 148 (100.0) | 0 (0.0) | 148 (67.3) |
| Painful breast | 0 (0.0) | 25 (34.7) | 25 (11.4) |
| Painful mass | 0 (0.0) | 24 (33.3) | 24 (10.9) |
| Painless mass | 0 (0.0) | 23 (31.9) | 23 (10.4) |
| Skin or nipple complaints | 0 (0.0) | 7 (10.1) | 7 (3.2) |
| CBE finding, n (%) | |||
| Normal | 121 (81.8) | 20 (27.8) | 141 (64.1) |
| Benign | 19 (12.8) | 28 (38.9) | 47 (21.4) |
| Probably benign | 8 (5.4) | 22 (30.6) | 30 (13.6) |
| Suspicious for cancer | 0 (0.0) | 2 (2.8) | 2 (0.9) |
| Definitely cancer | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| CBE plan, n (%) | |||
| Normal annual examination | 77 (52.0) | 25 (34.7) | 102 (46.4) |
| Clinical follow-up | 2 (1.3) | 1 (1.4) | 3 (1.4) |
| Recommend US | 39 (26.3) | 37 (51.4) | 76 (34.5) |
| Refer to cancer center | 0 (0.0) | 1 (1.4) | 1 (0.4) |
| Not specified | 30 (20.3) | 8 (11.1) | 38 (17.3) |
| US finding(s), n (%) | n = 266 | n = 107 | n = 373 |
| Normal tissue | 209 (78.6) | 50 (46.7) | 259 (69.4) |
| Infection | 0 (0.0) | 4 (3.7) | 4 (1.1) |
| Fat necrosis | 0 (0.0) | 2 (1.9) | 2 (0.5) |
| Cyst or ductal ectasia | 40 (15.0) | 16 (15.0) | 56 (15.0) |
| Mass | 16 (6.0) | 35 (32.7) | 51 (13.7) |
| Other | 1 (0.4) | 0 (0.0) | 1 (0.3) |
| BI-RADS, n (%) | n = 264 | n = 103 | n = 367 |
| 1 | 205 (77.6) | 49 (47.6) | 254 (69.2) |
| 2 | 38 (14.4) | 28 (27.2) | 66 (18.0) |
| 3 | 14 (5.3) | 16 (15.5) | 30 (8.2) |
| 4 | 6 (2.3) | 10 (9.7) | 16 (4.3) |
| 5 | 1 (0.4) | 0 (0.0) | 1 (0.3) |
| Final management, n (%) | n = 264 | n = 103 | n = 367 |
| Normal annual examination or clinical follow-up | 247 (93.6) | 75 (72.8) | 322 (87.7) |
| Imaging follow-up | 10 (3.8) | 16 (15.5) | 26 (7.1) |
| COR referral for further management | 7 (2.6) | 12 (11.7) | 19 (5.2) |
CBE = clinical breast examination; COR = Centro Oncológico Regional; US = ultrasound.
Includes women with nonfocal symptoms.
Totals in these categories are greater than patient totals, because patients may have had >1 complaint or finding.
Referral for cyst drainage, biopsy or fine needle aspiration, or excision of BI-RADS 3 mass >2.5 cm.